Board summary
Key figures
59,069
Registered population
56.8% aged 18–64
22.8%
Aged 65+
ICB 14.9% · England 17.9%
4.7%
In IMD quintile 1
ICB 40.7% · England 21.0%
~2,602
Core20 residents (est.)
Resident basis; registered basis ~2,982 · see page 3
9,337
Hypertension register
+3.57% in 3 yrs · England +5.60%
465
SMI register
13.9% of Stockport (LAD)'s
810
COPD register
Reviews -8.45% in 3 yrs
Forecast to 2030
10,160
Hypertension patients, 2030
+823 on today
65.9%
QRISK ≥20% on statins, 2030
+2.18pp over 3 yrs
6.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell below England.
Annual asthma reviews fell 8.0% over 2023 to 2025 to 58.9% (England 65.7%, +4.4%), leaving an estimated 1,528 unreviewed patients.
Deprivation and access pressure concentrate in one practice.
Bramhall & Shaw Heath Medical Group holds a 20.8% Core20 share (2,736 estimated patients), alongside 46.7% phone contact ease and 31.9% QOF vaccination achievement.
Strong SMI physical checks and hypertension control.
SMI blood pressure checks rose +10.7 pp over 2023 to 2025 to 91.7% (England 83.4%), while hypertension treatment to target reached 75.6% (England 70.3%).
Population, age and ethnicity
Aged 65+ patients account for 22.8% of the list, above borough and England
Bramhall and Cheadle Hulme PCN serves 59,069 registered patients. Patients aged 65+ represent 22.8% of the list (13,456 patients), above Stockport (LAD) (19.7%), NHS Greater Manchester Integrated Care Board (14.9%), and England (17.9%). Working-age adults aged 18-64 comprise 56.8% (33,569) and children aged 0-17 make up 20.4% (12,044). Recorded Roma residents represent 0.1% and Gypsy or Irish Traveller 0.0%. Projected population growth to 2030 is 0.6% (Stockport (LAD) 1.1%, NHS Greater Manchester Integrated Care Board 1.6%, England 2.3%), though projection methodology is unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 4.7% overall but concentrates sharply at one practice
Average IMD decile is 8.2 (Stockport (LAD) 6.4, NHS Greater Manchester Integrated Care Board 4.5, England 5.5). PCN Core20 share is 4.7% (Stockport (LAD) 16.1%, NHS Greater Manchester Integrated Care Board 40.7%, England 21.0%), though weighted practice share is 5.0% (a 0.33 percentage point difference; resident estimate 2,602). Across a 20.8 pp practice spread, Core20 patients concentrate at Bramhall & Shaw Heath Medical Group (20.8%, 2,736 estimated patients) and Hulme Hall Medical Group (2.4%, 246), with 0.0% across the other three practices. Proactive Core20 support is most efficiently directed to.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
465
SMI register
0.78% recorded prevalence
273
Learning disability register
0.46% recorded prevalence
26
Care homes, 1,272 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
The PCN records 465 patients on the severe mental illness register (0.8% vs England 1.0%, Stockport (LAD) 1.0%, NHS Greater Manchester Integrated Care Board 1.1%) and 273 on the learning disability register (0.5% vs England 0.6%, Stockport (LAD) 0.6%, NHS Greater Manchester Integrated Care Board 0.6%), alongside 26 catchment care homes holding 1,272 beds. Crude register differences do not establish under-detection, though monitoring annual health check completion can support care.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reached 91.7% (England 83.4%) and BMI recording 92.0% (England 82.1%). Missing check elements cannot imply full completion, and practice rates fall to 75.0% at The Village Surgery.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,337
Hypertension register
+3.57%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
−0.37pp
BP control, under 80
≤140/90 · −0.21pp aged 80+
+823
More patients by 2030
Forecast 10,160 (16.87%)
Hypertension case-finding and control
Recorded hypertension prevalence is 15.7% (9,337 patients), below Stockport (LAD) (16.2%) but above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%). Blood pressure monitoring reach is strong at 92.5% (England 90.0%), and treatment to target is 75.6% (England 70.3%; 72.6% for patients aged under 80 and 83.4% for those aged 80+). However, over 2023 to 2025, register growth of +3.6% trailed Stockport (LAD) (+5.0%) and England (+5.6%), while control under 80 fell 0.5% (England +3.2%). Hypertension register growth and under-80 control trail national progress despite strong current achievement, so prioritising opportunistic blood pressure case-finding and titration reviews could protect control across an older population.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 61.3%, trailing Stockport (LAD) (64.8%), England (63.6%), and NHS Greater Manchester Integrated Care Board (67.0%). Fewer at-risk patients receive lipid-lowering therapy than England and ICB rates imply, so a systematic recall audit of eligible patients with QRISK ≥ 20% is the priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 94,554 | £2.50 | £1.94 | £1.86 | £236,385 |
| Cardiovascular (all), 2025 | 131,719 | £4.64 | £3.15 | £3.33 | £611,176 |
In 2026, lipid-modifying drugs cost £2.50 per item across 94,554 items, above Stockport (LAD) (£1.99), NHS Greater Manchester Integrated Care Board (£1.94), and England (£1.86), spending £60,515 more than at England's unit cost. Higher unit costs for lipid-modifying items than comparators indicate an opportunity to review prescribing choices and formulary alignment across practices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.98%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.49%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 8.0% over 2023 to 2025 to 58.9% (Stockport (LAD) 63.4%, NHS Greater Manchester Integrated Care Board 66.2%, England 65.7%, England +4.4%), leaving an estimated scale gap of 1,528 unreviewed patients across the 3,718 register. COPD reviews fell 8.4% to 69.8% (Stockport (LAD) 76.4%, England 76.4%, England +2.8%), while the 810 COPD register fell 4.7% over 2023 to 2025 (England +2.6%; prevalence 1.4% vs England 1.9%). Slower respiratory reviews and register decline may indicate recall pressures.
Cancer register and children's immunisation
Cancer register prevalence is 5.0% (2,936 patients), above England (3.8%). In Q1 2025/26, 12-month 6-in-1 coverage was 88.5%, below the 95.0% target by 6.5 pp (England 91.0%), whereas 24-month course completion was 99.2%. At age 5, 4-in-1 booster coverage was 92.5% (below the 95.0% target by 2.5 pp) and MMR dose 2 coverage reached 95.0%.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 known-stage cases; England 55.3%), a distance of -19.4 pp to the 75.0% national ambition by 2028 and requiring about 2,270 additional early-stage cases. Of 16,492 registered cancers, 70.8% had a known stage; staging reflects ICB system data, not PCN performance. At PCN level, recorded cancer prevalence is 5.0% (2,936 patients; 3-year change +13.6% vs England +9.0%). Cervical screening (25-49) is 75.0% (England 66.8%), while Bramhall & Shaw Heath Medical Group records 68.2%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Stockport NHS Foundation Trust achieved 83.2% on the 28-day faster diagnosis standard (East Cheshire NHS Trust 81.1%, Manchester University NHS Foundation Trust 80.1%, NHS Greater Manchester Integrated Care Board 79.5%, England 79.3%; 75.0% standard) and 97.4% on the 31-day standard (England 92.5%). On the 62-day standard, it reached 74.7% (distance of -10.3 pp to the 85.0% standard; ICB 75.7%, England 71.2%). Diagnostic 6+ week waits were 1.4% for MRI and 2.9% for CT, but 67.7% for audiology. Provider waiting times reflect trust activity, not PCN performance.
| Pathways within standard (%) | Stockport | Manchester | East Cheshire | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 83.21 | 80.06 | 81.08 | 79.53 | 79.32 |
| 31-day treatment (96%) | 97.39 | 92.54 | 96.30 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 74.67 | 72.85 | 53.41 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Stockport | Manchester | East Cheshire | England |
|---|---|---|---|---|
| MRI | 1.41 | 11.68 | 26.62 | 21.40 |
| CT | 2.93 | 14.66 | 11.49 | 9.92 |
| Echocardiography | 17.46 | 4.91 | 26.24 | 28.48 |
| Colonoscopy | 5.53 | 4.51 | 10.85 | 30.83 |
| Gastroscopy | 5.31 | 29.35 | 10.25 | 29.02 |
| All 15 DM01 tests | 14.08 | 8.98 | 16.17 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). In Jun 2026 (provisional), community services recorded 57,085 contacts with Stockport residents, with 34,585 contacts among adults aged 65+, representing 60.6% of borough contacts. These figures describe wider local authority resident activity and were not captured at PCN level.
Practice variation and patient experience
Phone access and vaccination vary widely across practices despite strong overall clinical achievement
Overall QOF achievement for 2025/26 spans from 92.2% at Bramhall & Shaw Heath Medical Group to 100.0% at Bramhall Health Centre. Clinical-domain achievement reached 100.0% at both practices. In vaccination and immunisation, achievement showed a 68.1 pp range, from 31.9% at Bramhall & Shaw Heath Medical Group to 100.0% at Bramhall Health Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Village | 100 | 0.0 | 78.0% | 75.2% | 94.5% |
| Hulme Hall | 118 | 2.4 | 58.1% | 71.3% | 92.7% |
| Cheadle Hulme | 113 | 0.0 | 53.4% | 76.7% | 90.9% |
| Bramhall | 113 | 0.0 | 63.0% | 71.5% | 88.8% |
| Bramhall & Shaw | 95 | 20.8 | 46.7% | 71.5% | 70.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Over three years, 15 of 25 measures trailed England, led by respiratory reviews
Over 2023 to 2025, 15 of 25 compared measures trailed England's three-year change. The widest relative lags were in annual reviews: asthma reviews fell 8.0% (England +4.4%), COPD reviews fell 8.4% (England +2.8%), and heart failure reviews fell 2.3% (England +8.7%), despite heart failure review coverage reaching 84.2% (England 78.5%). Conversely, severe mental illness physical checks showed strong percentage-point gains above England: alcohol recording rose +12.7 pp (England +5.4 pp), body mass index recording rose +11.3 pp (England +5.1 pp), and blood pressure checks rose +10.7 pp (England +4.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
Heart failure reviews
COPD register
Hypertension treated to target
Alcohol record (psychosis)
BP check (SMI)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (1,272 beds) | n/a | Schools (catchment) | 101 | n/a |
| Children's centres | 2 | 2 | Places of worship | 44 | 135 |
| Libraries | 3 | 12 | Food banks (VCS) | n/a | 1 |
| Day centres (VCS) | 1 | no data | Primary schools (LA maintained) | 23 | 61 |
| Primary academies | 8 | 23 | Special schools | 3 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 58.9% (England 65.7%, Stockport (LAD) 63.4%), falling 8.0% over 2023 to 2025 (England +4.4%), an estimated scale gap of 1,528 unreviewed patients across the 3,718 register. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD case-finding and review recall
COPD prevalence is 1.4% (810 patients; fell 4.7% over 2023 to 2025 vs England +2.6%), below England (1.9%) and Stockport (LAD) (2.1%), an unadjusted gap of +309 to +457 patients; reviews are 69.8% (England 76.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
High-risk lipid therapy and formulary review
Lipid-lowering therapy for patients with QRISK ≥ 20% is 61.3% (3-year change +3.7%), below England (63.6%, +6.2%), Stockport (LAD) (64.8%), and ICB (67.0%); lipid-modifying items cost £2.50 vs England £1.86. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult anticipatory care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health review outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | Practice |
| Hypertension case finding and review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Infant immunisation timing recall (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD case-finding and review recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · High-risk lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
